Linganisha mbinu

	Jaribio kamili la vipengele vingi vilivyofichwa kwa upande mmoja	Jaribio la Kisayansi la Kidhibiti cha Machafuko lenye Kufunikwa kwa Upande Mmoja
Nyanja	Muundo wa Majaribio	Muundo wa Majaribio
Familia	Process / pipeline	Process / pipeline
Mwaka wa asili	Full factorial: 1935 (Fisher); single-blind clinical convention: mid-20th century	1948 (formalized); single-blind variant established in mid-20th century clinical trial methodology
Mwanzilishi	Full factorial framework: R. A. Fisher; single-blind masking practice: clinical trial tradition, standardized by the 20th century	Bradford Hill and colleagues (MRC streptomycin trial, 1948); blinding conventions codified in CONSORT guidelines
Aina	Controlled experimental design	Experimental design — blinded randomized trial
Chanzo asilia	Montgomery, D. C. (2017). Design and Analysis of Experiments (9th ed.). Wiley. ISBN: 978-1119113478	Schulz, K. F., Altman, D. G., Moher, D., & CONSORT Group. (2010). CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ, 340, c332.
Majina mbadala	single-masked full factorial, single-blind complete factorial, SB-FFE, single-blind all-combinations design	single-masked RCT, single-blind RCT, single-blind trial, SB-RCT
Zinazohusiana	6	5
Muhtasari	A single-blind full factorial experiment systematically tests every combination of all factor levels while keeping participants unaware of their treatment assignment. This design allows simultaneous estimation of all main effects and all interaction effects between factors, with single-blind masking reducing participant-side biases such as demand characteristics and expectation effects — without requiring investigator blinding.	A single-blind randomized controlled trial (SB-RCT) is a rigorous experimental design in which participants are randomly assigned to treatment or control conditions while remaining unaware of which condition they have received. Investigators, outcome assessors, and data analysts are not blinded. By masking participants, the design eliminates placebo and nocebo response biases on the participant side, while preserving investigator flexibility to administer and monitor the intervention.